Scinai Immunotherapeutics Ltd. · NASDAQ:SCNI
Scinai Immunotherapeutics — Investor Presentation (September 2023)
28 slides from Scinai Immunotherapeutics's investor presentation, Sep 11, 2023
Slide 1: Scinai Immunotherapeutics
SCINAI IMMUNOTHERAPEUTICS September 2023 | Nasdaq: SCNI
Slide 2: Safe Harbor Statement
~ SCINAI SAFE HARBOR STATEMENT This communication contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify such f
Slide 3: Scinai Immunotherapeutics
» §CINAI SCINAI IMMUNOTHERAPEUTICS Advancing new pipeline of innovative VHH antibody (NanoAb) based drugs from R&D through commercialization Targeting autoimmune and infectious diseases with large under-served needs and attractive commercial opportunities such as: PSORIASIS ASTHMA coviD19 PSORIATIC
Slide 4: Nanosized Antibody Pipeline: Huge Opportunity
* SCINAI NANOSIZED ANTIBODY PIPELINE: HUGE OPPORTUNITY 0 WW YD © Ow HUMAN ANTIBODY (mAb) ALPACA-DERIVED ANTIBODY (NanoAb) Alpaca-derived nanosized antibodies (NanoAbs) are also known as VHH antibodies! mAb therapeutic market size is ~$205 billion? including Cosentyx for psoriasis $4.8 billion (2022)
Slide 5: Max Planck and Scinai Collaboration
MAX PLANCK AND SCINAI COLLABORATION Designed to gnificant clini | mmercial advantag' Scinai brings... + Recombinant protein drug development experience from lab to Phase 3 clinical trial + Manufacturing, quality, international regulatory experience + GMP biologics manufacturing facility + Best-in-cl
Slide 6: Platform Value Proposition
* SCINAI PLATFORM VALUE PROPOSITION NanoAbs’ unique physicochemical attributes can generate multiple crucial advantages vs human monoclonal antibodies (mAbs) Manufacturing 10-times more active pharmaceutical ingredients (API) per gram of manufactured protein vs. mAbs Faster and lower cost production
Slide 7: Derisked Drug Development
~ SCINAI DERISKED DRUG DEVELOPMENT NanoAbs feature a favorable path to market compared to risks associated with traditional drug development Source of Risk NanoAb Molecular Target Validated by existing but sub-optimal mAb therapies Mechanism st Well understood Action Composition of TBD Assessing saf
Slide 8: Yeast: Pichia pastoris
10 15 20 30 25 40 70 60 50 85 100 Y ea s t: P i chi a pas t or i s
Slide 9: Pipeline Molecular Targets
° SCINAI PIPELINE MOLECULAR TARGETS HETERODIMER PSORIASIS, PSA, COVvID-19 ATOPIC DERMATITIS, HS. * Strong in vivo data for inhaled therapeutic and prophylactic * Single compound targeting IL-17A and IL- 17 and IL-17AF + Novel local use * Larger target population than the one addressed by mAbs such a
Slide 10: Pipeline Addressing Large Markets with Underserved Needs
CINAI PIPELINE ADDRESSING LARGE MARKETS WITH UNDERSERVED NEEDS COVID-19 NanoAb: Proof-of- concept as therapeutic and prophylactic. Psoriasis proof-of-concept anticipated in 2023. Autoimmune Market Sizes * Validated targets of existing mAb treatments + Short time to value generation, lower risk than
Slide 11: Pipeline Development: Status & Upcoming Milestones
= SCINAI PIPELINE DEVELOPMENT: STATUS & UPCOMING MILESTONES Anti-IL-17 psoriasis treatment in-vivo proof-of-concept in 2023, clinical trial 2024 Indication Covid-19 Therapeutic Covid-19 Prophylactic Psoriasis, PSA, Atopic Dermatitis, HS Asthma, Atopic Dermatitis Wet AMD Drug Discovery (Max Planck) M
Slide 12: Anti-IL-17 NanoAb: Large and Growing Psoriasis Market
CINAI ANTI-IL-17 NANOAB INITIAL FOCUS: THE LARGE AND GROWING PSORIASIS MARKET WITH UNDERSERVED NEEDS Current standards of care: * Topical (steroids, vitamin D analogues, retinoids) + Phototherapy + Systemic * Traditional systemics (e.g. methotrexate, acitretin, and ciclosporin) * Injected biologics
Slide 13: Four Approved IL-17 Inhibitors on the Market
CINAI FOUR APPROVED IL-17 INHIBITORS ON THE MARKET All target psoriasis, some of them target additional indications Name conipary Cosentyx 1 (secukinumab) & NovarTIS io BAUSCH-Heaith (brodalumab) rove Litt, e | Bimzelx ‘Source: Datamonitor: LEK. research and analysis, Approved Date EUS 2015 2017 201
Slide 14: Why Develop an Anti-IL-17 NanoAb?
CINAI WHY DEVELOP AN ANTI-IL-17 NANOAB? Strong business and clinical potential for development and commercialization Success Factor IL-7 is a well-established target in psoriasis There is evidence of IL-17 being responsive to nanobodies Characteristic of the asset could help address specific unmet n
Slide 15: NanoAbs Target Underserved Population
CINAI NANOABS TARGET UNDERSERVED POPULATION Underserved patient population 125 million patients, including 7.5 million US adults 80-90% is plaque psoriasis Current therapies targeted only to moderate & severe patients, administered systemically Mild patients may suffer from considerable and visible
Slide 16: Anti-IL-17 NanoAb for Psoriasis: Derisked Drug Development
CINAI ANTI-IL-17 NANOAB FOR PSORIASIS: DERISKED DRUG DEVELOPMENT Attractive market potential, proven target, short time to proof-of-concept Source of Risk NanoAb Validated by existing therapies: Molecular Target Cosentyx, Silig, Taltz and Bimzelx Mechantem.of Well understood Action Composition of Ma
Slide 17: Anti-IL-17 NanoAb Advantages
CINAI ANTI-IL-17 NANOAB ADVANTAGES Single NanoAb neutralizes IL-17 A, F, and AF complex nomatzed Inductenabove background cof oe HH (an Molecular Target Administration Target Patient Population Storage Conditions LA7 A Other Treatments Most of the commercially available mAbs target IL-17A Bimzelx an
Slide 18: Vast & Growing Market for COVID-19 Therapies
VAST & GROWING MARKET FOR COVID-19 THERAPIES 66 SARS-CoV-2 is unlikely to be eliminated, let alone eradicated; a it will probably continue to circulate indefinitely in periodic outbreaks and endemics. ANTHONY FAUCI, December 2021.0 NEED FOR TREATMENT IS GROWING... Current COVID therapies experiencin
Slide 19: COVID Market Potential
CINAI COVID MARKET POTENTIAL Current FDA-approved COVID treatments: “! + Oral antiviral pills: - Pfizer’s Paxlovid (nirmatrelvir + ritonavir) - Merck’s Lagevrio (molnupiravir) * Intravenous (IV) antiviral: - Gilead’s Veklury (remdesivir) * Immune modulators: - Olumiant (baricitinib) and Actemra (toc
Slide 20: Inhaled Anti-COVID-19 NanoAb Protected Hamsters from Severe Disease
CINAI INHALED ANTI-COVID-19 NANOAB PROTECTED HAMSTERS FROM SEVERE DISEASE Significantly milder disease course measured by weight loss in hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs, administered 24 hours post infection, compared to placebo Weight (%) * Inhal
Slide 21: Titer [TCID /g] limit of detection ٓٓٓٓ ٓٓٓٓ ٓٓٓٓ ٓٓٓٓ 9 8 7 6
10 1 10 2 10 3 10 4 10 5 10 6 Titer [TCID 50 /g] limit of detection ٓٓٓٓ ٓٓٓٓ ٓٓٓٓ ٓٓٓٓ 9 8 7 6 5 4 3 2 1 SARS - CoV - 2 RNA copies/ml BALF ٓٓ ٓٓٓٓ ٓ ٓٓ de t e c t i o n limit
Slide 22: Boutique CDMO Services
CINAI BOUTIQUE COMO SERVICES DE-RISKING SCINAI’S INTERNAL R&D INVESTMENTS BY LEVERAGING INTERNAL CAPABILITIES ie Bop ASEPTIC GMP MANUFACTURING SUITES STATE-OF-THE-ART R&D AND Qc LABORATORIES PHARMA CMC EXPERIENCE Scinai’s CDMO business unit leverages our cGMP manufacturing facility, aseptic fermenta
Slide 23: GMP Manufacturing and R&D Labs
CINAI GMP MANUFACTURING AND R&D LABS Industry standard aseptic facility: Labs, cleanroom, warehouses, offices + Analytical methods development combined with best-in-class @C capabilities and equipment * Labs for manufacturing process development and scale-up allow for the implementation of quality b
Slide 24: Deep Pharma Experience & Capabilities
CINAI DEEP PHARMA EXPERIENCE & CAPABILITIES 35 STAFF MEMBERS 5 PhDs Manufacturing, engineering, technical R&D, upstream & downstream process development, QC, QA, clinical and non-clinical, procurement Outsourced finance, legal, regulatory AMIR REICHMAN — CEO Senior global pharma leadership positions
Slide 25: Board Brings Significant Expertise
CINAI BOARD BRINGS SIGNIFICANT EXPERTISE Mark Germain, Chairman Aentib Group (Managing Director). Founder, director, chairman, and/or investor in over 20 biotech companies including Alexion, Incyte, Neurocrine, Ariad, ChromaDex. Samuel Moed, Director Bristol Myers Squibb (NYSE: BMY) (Senior Vice Pre
Slide 26: Select Financials & ADS Outstanding
SELECT Nasdaq: SCNI FINANCIALS & ADS OUTSTANDING Ordinary ADS 3,651,927 CAP TABL Pre-funded ADS 675,000 Primary shares out 4,326,927 $5 Warrants (Expire 20 Dec 2023) 4790 $5 Warrants (Expire 22 Dec 2025) TISOG,080 Options + RSUs 277,448 Updated: July 31, 2023, + $7.6M cash as of June 30, 2023 * €24M
Slide 27: Significant Potential for Value Creation
CINAI SIGNIFICANT POTENTIAL FOR VALUE CREATION ¢ Well-positioned to bring innovative inflammation & immunology (I&l) therapies to market ¢« Demonstrated multiple biologics tech transfers, process development and optimization, scale-up, production, preclinical and clinical trials planning and executi
Slide 28: September 2023
NASDAQ: SCNI www.scinai.com SEPTEMBER 2023 CINAI RAPEUTICS Contact: Joshua Phillipson Investor Relations ir@scinai.com +972-8-930-2529
Scinai Immunotherapeutics — Investor Presentation (September 2023) on 6ix